Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · BAFNAPH

BAFNAPH

HealthcarePharmaceuticals & Biotechnology₹1128 cr market cap
₹478.50 ▲ +1.72% today As of 19 Nov 2026
52-week low ₹99.1652-week high ₹491.85

-4.4% from the 52-week high · +374.4% above the low

Bafna Pharmaceuticals Ltd. engages in the manufacture of drugs and medicines of life saving drugs. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2008-06-27. The firm is primarily engaged in the business of manufacturing finished pharmaceutical formulations. The company is also involved in manufacturing 336 licensed pharmaceutical formulations and has globally registered approximately 78 of its products. Its Madhavram facility manufactures finished solid oral and liquid oral dosage forms of Betalactam and Non-Betalactam and Cephalosporin products. The company supplies its products to the United Kingdom, Europe, and Australian markets. The firm's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements.

The short version. Promoter holding was 75.0% in Sep 2026, down 13.30 points over 8 quarters.

1 · The price

How has the stock traded?

BAFNAPH trades 4.4% below its 52-week high and 374.4% above its 52-week low.

Change over period: —

1M+-0.0%
3M+93.9%
6M+240.0%
1Y+170.4%

2 · The business

Is it growing?

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Mar 2020Dec 2019Sep 2019Jun 2019
Revenue1311127
Net profit0-22-1-2
Net margin %2.4-204.4-5.1-31.1
EPS (₹)1.34-9.44-0.25-0.9

Annual

FY2020FY2019
Revenue4243
Net profit-25-18
Net margin %-58.2-42.3
EPS (₹)-104.54-7.76

3 · The quality

How well does it turn capital into profit?

.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %————
Return on capital %————
EBITDA margin %————
Net margin %————

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
P/E ratio99.1

4 · The owners

Who holds it, and are they adding?

Promoter holding75.0%

Down 13.3 pts over 8 quarters.

Foreign institutions9.34%

Up 9.34 pts over 8 quarters.

Mutual fund schemes0

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter88.375.075.075.075.075.075.075.0-13.3
FII08.539.349.349.349.349.349.34+9.34
DII000000000
Public11.716.4715.6615.6615.6615.6615.6615.66+3.96

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for BAFNAPH are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about BAFNAPH

What is the BAFNAPH share price?

BAFNAPH (BAFNAPH) last closed at ₹478.50, up 1.72% on the day. Its 52-week range is ₹99.16 to ₹491.85.

What is the market cap of BAFNAPH?

BAFNAPH has a market capitalisation of about ₹1,128 crore. Its price-to-earnings ratio is 99.1.

How are BAFNAPH's latest results?

Promoter holding was 75.0% in Sep 2026, down 13.30 points over 8 quarters.

Who owns BAFNAPH?

As of Sep 2026, shareholding was: Promoter 75.0%, FII 9.34%, Public 15.66%.

How many mutual funds hold BAFNAPH?

0 mutual fund schemes held BAFNAPH in October 2026. That compares with 0 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.